SOUTH PLAIN, NJ, March 11, 2022 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters describing data on EMFLAZA™ (deflazacort) in Duchenne muscular dystrophy (DMD) to the Muscular Dystrophy Association ( MDA) Clinical & Scientific Conference in progress March 13-16 in Nashville, Tennessee. and virtually.
For the first time, PTC will present data on the association between steroid treatment and clinical outcomes in nonambulatory patients with DMD, expanding the body of evidence that supports the potential cumulative benefit of deflazacort over prednisone in this patient population. These findings have not been previously published and advance the clinical understanding of steroid therapy across the DMD continuum of care.
Poster presentations include:
- Poster title: Associations between deflazacort and prednisone/prednisolone and markers of disease progression in subgroups of patients with Duchenne muscular dystrophy
Poster number: 109
- Poster title: Associations between daily deflazacort or prednisone and age of disease progression milestones in patients with Duchenne muscular dystrophy
Poster number: 110
- Poster title: Associations between steroid treatment and clinical outcomes in nonambulatory patients with Duchenne muscular dystrophy
Poster number: 95
Posters will be visible in person throughout the conference. All abstracts are available on the MDA conference website at https://mdaconference.org/abstract-search.
PTC will also host a hybrid industry forum,”Along the disease continuum: corticosteroid therapy in Duchenne muscular dystrophy,” to tuesday march 15 from 12:00 p.m.-1:25 p.m. CDT. Those interested in attending in person or virtually can register at http://www.PTCIF2022.com. Participation is limited to licensed healthcare professionals in the United States only.
About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefit to patients with rare diseases. PTC’s ability to innovate to identify new therapies and bring products to market globally is the foundation that drives investment in a strong and diverse pipeline of transformative medicines. PTC’s mission is to provide access to the best treatments for patients who have few or no treatment options. PTC’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this enables it to maximize value for all of its stakeholders. To learn more about PTC, visit www.ptcbio.com and follow us on Instagram, Facebook, Twitter and LinkedIn.
For more information:
Investors:
Kylie O’Keefe
+1 (908) 300-0691
Media:
Jeanine Clement
+1 (908) 912-9406
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this release, other than statements of historical fact, are forward-looking statements, including statements regarding: future expectations , PTC’s plans and prospects, including with respect to the commercialization of its products and product candidates; PTC’s strategy, future operations, future financial condition, future revenues, projected costs; and management objectives. Other forward-looking statements can be identified by the words “guidance”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “intend”, “could”, “target”, “potential”, “will”, “should”, “could”, “should”, “continue” and other similar expressions.
The actual results, performance or achievements of PTC could differ materially from those expressed or implied by the forward-looking statements it makes due to a variety of risks and uncertainties, including those relating to: the outcome of pricing, coverage and reimbursement negotiations with third party payers for PTC’s products or product candidates that PTC markets or may market in the future; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC’s products and product candidates; PTC’s scientific approach and general development progress; and the factors discussed in the “Risk Factors” section of PTC’s most recent Annual Report on Form 10-K, as well as any updates to such risk factors filed from time to time in other filings by PTC with the DRY. You are encouraged to carefully consider all of these factors.
As with any pharmaceutical product under development, the development, regulatory approval and commercialization of new products involve significant risks. There is no guarantee that a product will receive or maintain regulatory approval in any jurisdiction or prove commercially successful, including Emflaza.
The forward-looking statements contained herein represent the views of PTC only as of the date of this press release, and PTC does not undertake or intend to update or revise these forward-looking statements to reflect actual results or changes in plans. , outlook, assumptions, estimates. or projections, or other circumstances occurring after the date of this press release, except as required by law.
View original content to download multimedia: https://www.prnewswire.com/news-releases/ptc-therapeutics-to-present-new-data-at-the-2022-muscular-dystrophy-association-clinical– scientific-conference-301500708.html
SOURCE PTC Therapeutics, Inc.
:no_upscale()/cloudfront-us-east-1.images.arcpublishing.com/dmn/SZ666KJC7ZHUFK5KQSZ7QULROU.jpg)